MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41392-025-02382-w

Медицинская библиотека · Signal transduction and targeted therapy · 2025

Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer.

Lu Jun, Hu Minjuan, Zhao Yikai, Chu Tianqing, Zhang Wei, Zhou Yijia, Cai Xinlei, Wu Jun, Hu Liang, Shi Chunlei, Xiong Liwen, Gu Aiqin, Wang Huimin, Zhang Yanwei, Lou Yuqing, Zhong Runbo, Gao Zhiqiang, Liu Hongyu, Zhou Chao, Wu Yingli, Zhu Liang, Zhong Hua, Ji Hongbin, Han Baohui

СтатьяКлиническое исследование I фазыПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Oncogenic KRAS mutations are frequently detected in NSCLC. It remains a major challenge to target all KRAS mutants. MEK inhibitors are considered candidates for treating KRAS-mutant NSCLC; however, their easy adaptive resistance precludes further application. Here, we found that MEK inhibitor-trametinib treatment results in the feedback activation of multiple receptor tyrosine kinases (RTKs) and that treatment with the pan-RTK inhibitor anlotinib effectively inhibits the progression of KRAS-mutant NSCLC. Furthermore, we evaluated this strategy in a clinical study (NCT04967079) involving 33 advanced non-G12C KRAS-mutant NSCLC patients. The phase Ia containing 13 patients showed that the recommended phase 2 dose (RP2D) is trametinib (2 mg) plus anlotinib (8 mg), the objective response rate (ORR) is 69.2% (95% CI: 38.6-90.9), the median progression-free survival (PFS) is 6.9 months (95% CI: 3.9 to could not be evaluated), disease control rate (DCR) is 92% (95% CI: 64.0-99.8) and the rate of adverse events (AEs) ≥grade 3 is 23%. The phase Ib containing 20 patients demonstrated the high efficacy of this combinational therapy with RP2D, with the ORR at 65% (95% CI: 40.8-84.6), the median PFS is 11.5 months (95% CI: 8.3-15.5), the median overall survival (OS) is 15.5 months (95% CI: 15.5 to could not be evaluated), the DCR at 100% (95% CI: 83.2-100.0), the median duration of overall response (DoR) is 9.3 months (95% CI: 2.5-12.1), and the rate of AEs ≥ grade 3 at 35%. Overall, this study provides a potential combinational therapeutic strategy for KRAS-mutant NSCLC through the cotargeting of MEK and RTKs.

Для цитирования: Lu Jun, Hu Minjuan, Zhao Yikai, Chu Tianqing, Zhang Wei, Zhou Yijia, Cai Xinlei, Wu Jun, Hu Liang, Shi Chunlei, Xiong Liwen, Gu Aiqin, Wang Huimin, Zhang Yanwei, Lou Yuqing, Zhong Runbo, Gao Zhiqiang, Liu Hongyu, Zhou Chao, Wu Yingli, Zhu Liang, Zhong Hua, Ji Hongbin, Han Baohui. Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer.. Signal transduction and targeted therapy. 2025. DOI: 10.1038/s41392-025-02382-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.